Skip to main content

Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies

By: 3BL Media
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

SOURCE: Gilead Sciences

DESCRIPTION:

The data we presented at ECCMID 2022 is part of Gilead’s mission to advance access to effective therapies. We've helped transform the treatment and prevention of HIV and delivered HCV cures as a result of our deep scientific understanding of viruses and expertise in antiviral drug development.

View original content here.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead Website

Tweet me: The data @GileadSciences presented at #ECCMID2022 is part of their mission to advance access to effective therapies. https://bit.ly/3khM9oh

KEYWORDS: NYSE: GILD, Gilead Sciences, ECCMID 2022

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.56
+0.86 (0.34%)
AAPL  270.23
+6.83 (2.59%)
AMD  278.39
+0.13 (0.05%)
BAC  53.91
+0.40 (0.75%)
GOOG  339.40
+6.63 (1.99%)
META  688.55
+11.68 (1.73%)
MSFT  422.79
+2.53 (0.60%)
NVDA  201.68
+3.33 (1.68%)
ORCL  175.06
-3.28 (-1.84%)
TSLA  400.62
+11.72 (3.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.